Adenocarcinoma News and Research

RSS

Adenocarcinoma is cancer that begins in cells that line certain internal organs and that have gland-like (secretory) properties.

Scientists reveal why common pancreatic precancer lesions rarely turn deadly

Spatial and single-cell analyses of human donor pancreata showed that PanIN epithelial cells gradually acquire cancer-like molecular features, while their surrounding stromal and immune environment remains closer to normal pancreatic tissue. The findings suggest that delayed or incomplete microenvironmental reprogramming may help explain why most PanIN lesions remain indolent rather than progressing to pancreatic cancer.

24 May 2026

Scientists map genetic variants behind prostate cancer therapy failure

Recently, the research group led by Dr. Dechao Feng, Lecturer at University College London (UCL) and Distinguished Research Fellow at Zhejiang Provincial People's Hospital, published a review entitled "Intratumoral Androgens and Genetic Variants Driving Therapy Resistance in Prostate Cancer".

22 May 2026

New CA19-9 threshold improves pancreatic cancer risk prediction accuracy

A dual-threshold model for measuring the pancreatic tumor marker serum carbohydrate antigen 19-9 (CA19-9) identified patients with pancreatic cancer who had high-risk disease despite having low CA19-9 levels because of a genetic variation that impairs their ability to produce this biomarker.

21 May 2026

Adult weight gain strongly linked to higher obesity-related cancer risk

New research presented at this year's European Congress on Obesity (ECO 2026) in Istanbul, Turkey (12-15 May) shows that people who gain the highest amount of weight across adulthood are at greatly increased risk of certain obesity related cancers.

13 May 2026

New AI model spots hidden pancreatic cancer long before diagnosis

Mayo Clinic's AI model identifies invisible signs of pancreatic cancer on routine CT scans, potentially transforming early detection and survival rates.

7 May 2026

Targeted RAS inhibitor shows promise against pancreatic cancer mutations

The targeted RAS inhibitor therapy daraxonrasib demonstrated the potential to improve patient outcomes over current standard treatments for patients with RAS-mutant pancreatic cancer, according to results of a Phase 1/2 trial led by researchers at The University of Texas MD Anderson Cancer Center.

7 May 2026

Six genes found to connect pancreatic cancer with metabolic dysfunction

New research shows that the same genes are active in pancreatic cancer, obesity and diabetes, helping to explain why people with metabolic disease often face poorer cancer outcomes and pointing to future ways to predict recurrence and develop more targeted treatments.

6 May 2026

AI model detects pancreatic cancer years before clinical diagnosis

An AI model (REDMOD) can pick up the very early subtle tissue changes of pancreatic ductal adenocarcinoma, the most common form of pancreatic cancer, which conventional imaging and the human eye find difficult to detect, finds research published online in the journal Gut.

28 Apr 2026

New immune mapping tool reveals how lung cancer reshapes immune cells

Researchers at VIB and VUB have developed a powerful new way to study how the immune system behaves inside lung tumors.

27 Apr 2026

MSK scientists shed new light on a tumor's earliest moments

Scientists at Memorial Sloan Kettering Cancer Center (MSK) and their colleagues are shedding new light on a tumor's earliest moments - revealing how lung cells with cancer-causing mutations recruit accomplices from healthy surrounding tissue to pave the way for a tumor to develop.

23 Apr 2026

Scientists find "hidden" pre-cancer signs in advanced esophageal cancer patients

Scientists have found the strongest evidence to date that a condition known as Barrett's esophagus is the starting point for all cases of esophageal adenocarcinoma – the most common type of esophageal cancer in the developed world – even when telltale signs of this pre-cancerous stage are no longer visible.

16 Apr 2026

Experimental drug shows survival benefit in pancreatic cancer trial

Pancreatic cancer is one of the deadliest cancers and among the hardest to treat, with most patients surviving less than a year after diagnosis.

14 Apr 2026

Clusterin inhibition offers new hope for treating cervical gastric-type adenocarcinoma

Gastric-type adenocarcinoma (GAS) is one of the most aggressive non-human papillomavirus (HPV)-associated cervical adenocarcinomas and remains especially difficult to diagnose and treat.

8 Apr 2026

AI tool predicts Barrett’s esophagus recurrence with high accuracy

A new artificial intelligence (AI)–based tool shows promise for improving surveillance in patients treated with endoscopic eradication therapies for Barrett's esophagus (BE) related dysplasia and early esophageal adenocarcinoma.

7 Apr 2026

Metabolic pathways drive progression from pancreatic lesions to cancer

Pancreatic ductal adenocarcinoma is the most common type of pancreatic cancer and has a low five-year survival rate.

3 Apr 2026

Lipid nanoparticles help CAR T cells melt pancreatic cancer barriers

Often diagnosed when surgery is no longer an option, pancreatic cancer is one of the most difficult cancers to treat and has one of the lowest rates of survival among major malignancies.

31 Mar 2026

Experts propose trial to evaluate obesity medications for cancer prevention

In new research to be presented at this year's European Congress on Obesity (ECO2026) in Istanbul, Turkey (12-15 May), a global panel of 21 obesity and cancer experts suggest that to test the potential efficacy of the new generation of obesity drugs such as semaglutide and tirzepatide in preventing obesity-related cancer (ORC), a trial of the drugs for some 5,000 participants at high risk of cancer due to their having a cancer pre-cursor condition will provide the required answers.

25 Mar 2026

Detailed cell atlas reveals earliest changes in prostate cancer

Prostate cancer affects one in five Australian men, making it the most common cancer in the country.

25 Mar 2026

Experimental therapy eliminates pancreatic precancerous cells in mice study

A new preclinical study in mice shows that precancerous cells in the pancreas can be eliminated before they have the chance to become tumors.

12 Mar 2026

New protein target for safer lung cancer therapy

Researchers at the University of Gothenburg have identified a protein linked to an increased risk of metastasis and recurrence in lung cancer. The findings are presented in a study that paves the way for new precision medicine approaches, particularly for older patients.

12 Mar 2026